Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).
Phase:
PHASE3
Details
Lead Sponsor:
Duke University
Collaborator:
Patient-Centered Outcomes Research Institute
Treatments:
Abatacept Dosage Forms tocilizumab tofacitinib Tumor Necrosis Factor Inhibitors